Erratum: Furazolidone, Co-amoxiclav, colloidal bismuth subcitrate, and esomeprazole for patients who failed to eradicate helicobacter pylori with triple therapy (Digestive Diseases and Sciences (2009) 54:1953-1957 DOI: 10.1007/s10620-008-0582-6);Furazolidone, co-amoxiclav, colloidal bismuth subcitrate, and esomeprazole for patients who failed to eradicate helicobacter pylori with triple therapy

Digestive Diseases and Sciences

Volumn 54, Issue 9, 2009, Pages 1953-1957

  Abbas, Zaigham ^a   Yakoob, Javed ^a   Abid, Shahab ^a   Jafri, Wasim ^a   Islam, Muhammad ^a   Azam, Zahid ^a   Hilal, Imran ^a  

^a AGA KHAN UNIVERSITY HOSPITAL   (Pakistan)

Author keywords

Bismuth; Clarithromycin; Co amoxiclav; Esomeprazole; Furazolidone; Helicobacter pylori

Indexed keywords

AMOXICILLIN PLUS CLAVULANIC ACID; BISMUTH CITRATE; CEBES S; ESOMEPRAZOLE; FLUROXONE; FURAZOLIDONE; UNCLASSIFIED DRUG; ANTIINFECTIVE AGENT; HYDROGEN POTASSIUM ADENOSINE TRIPHOSPHATASE; OMEPRAZOLE; ORGANOMETALLIC COMPOUND;

ADULT; AGED; ARTICLE; CLINICAL TRIAL; CONTROLLED STUDY; DECREASED APPETITE; DRUG EFFICACY; DRUG SAFETY; DRUG TREATMENT FAILURE; ERADICATION THERAPY; FECES; FEMALE; HEARTBURN; HELICOBACTER INFECTION; HELICOBACTER PYLORI; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; MALE; NAUSEA; PRIORITY JOURNAL; SIDE EFFECT; TASTE DISORDER; UREA BREATH TEST; WEAKNESS; DRUG ANTAGONISM; DRUG COMBINATION; MIDDLE AGED; PROSPECTIVE STUDY; TREATMENT FAILURE;

ADULT; AGED; AMOXICILLIN-POTASSIUM CLAVULANATE COMBINATION; ANTI-INFECTIVE AGENTS; DRUG THERAPY, COMBINATION; FEMALE; FURAZOLIDONE; H(+)-K(+)-EXCHANGING ATPASE; HELICOBACTER INFECTIONS; HELICOBACTER PYLORI; HUMANS; MALE; MIDDLE AGED; OMEPRAZOLE; ORGANOMETALLIC COMPOUNDS; PROSPECTIVE STUDIES; TREATMENT FAILURE; YOUNG ADULT;

EID: 68249149653     PISSN: 01632116     EISSN: None     Source Type: Journal    
DOI: 10.1007/s10620-010-1171-z     Document Type: Erratum

References (27)

1. P Malfertheiner F Megraud C O'Morain F Bazzoli E El-Omar D Graham R Hunt T Rokkas N Vakil EJ Kuipers 2007 Current concepts in the management of Helicobacter pylori infection: the Maastricht III Consensus Report Gut 56 772 781 10.1136/gut.2006.101634 (Pubitemid 46854190)
2. DY Graham A Shiotani 2008 New concepts of resistance in the treatment of Helicobacter pylori infections Nat Clin Pract Gastroenterol Hepatol 5 321 331 10.1038/ncpgasthep1138 (Pubitemid 351803603)
3. S Mendonça C Ecclissato MS Sartori AP Godoy RA Guerzoni M Degger J Pedrazzoli Jr 2000 Prevalence of Helicobacter pylori resistance to metronidazole, clarithromycin, amoxicillin, tetracycline and furazolidone in Brazil Helicobacter 5 79 83 10.1046/j.1523-5378.2000.00011.x (Pubitemid 34951164)
4. MS Osato R Reddy SG Reddy RL Penland HM Malaty DY Graham 2001 Pattern of primary resistance of Helicobacter pylori to metronidazole or clarithromycin in the United States Arch Intern Med 161 1217 1220 10.1001/archinte.161.9.1217 (Pubitemid 32691518)
5. MP Dore DY Graham AR Sepulveda G Realdi MS Osato 1999 Sensitivity of amoxicillin-resistant Helicobacter pylori to other penicillins Antimicrob Agents Chemother 43 1803 1804
6. A Kwok T Lam P Katelaris RW Leong 2008 Helicobacter pylori eradication therapy: indications, efficacy and safety Expert Opin Drug Saf 7 271 281 10.1517/14740338.7.3.271 (Pubitemid 351802827)
7. V Ojetti A Migneco MA Zocco EC Nista G Gasbarrini A Gasbarrini 2004 Beta-lactamase inhibitor enhances Helicobacter pylori eradication rate J Intern Med 255 125 129 10.1046/j.0954-6820.2003.01239.x (Pubitemid 38121931)
8. LC Frota P da Cunha Mdo CR Luz AH de Araujo-Filho LA Frota LL Braga 2005 Helicobacter pylori eradication using tetracycline and furazolidone versus amoxicillin and azithromycin in lansoprazole based triple therapy: an open randomized clinical trial Arq Gastroenterol 42 111 115 10.1590/S0004- 28032005000200009
9. JN Eisig FM Silva TN Rodriguez CL Hashimoto RC Barbuti 2005 A furazolidone-based quadruple therapy for Helicobacter pylori retreatment in patients with peptic ulcer disease Clinics 60 485 488 10.1590/S1807- 59322005000600010
10. ZT Zheng YB Wang 1992 Treatment of peptic ulcer disease with furazolidone J Gastroenterol Hepatol 7 533 537 10.1111/j.1440-1746.1992.tb01034.x
11. O Hegedus J Rydén AS Rehnberg S Nilsson PM Hellström 2002 Validated accuracy of a novel urea breath test for rapid Helicobacter pylori detection and in-office analysis Eur J Gastroenterol Hepatol 14 513 520 10.1097/00042737-200205000-00008 (Pubitemid 34518183)
12. RM Said PL Cheah SC Chin KL Goh 2004 Evaluation of a new biopsy urease test: Pronto Dry for the diagnosis of Helicobacter pylori infection Eur J Gastroenterol Hepatol 16 195 199 10.1097/00042737-200402000-00012 (Pubitemid 39049657)
13. P Bytzer CM O'Morain 2005 Treatment of Helicobacter pylori Helicobacter 10 40 46 10.1111/j.1523-5378.2005.00333.x
14. X Calvet 2006 Helicobacter pylori infection: treatment options Digestion 73 Suppl 1 119 128 10.1159/000089787 (Pubitemid 43296225)
15. N Broutet S Tschamgoué E Pereira H Lamouliatte R Salamon F Mégraud 2003 Risk factors for failure of Helicobacter pylori therapy-results of an individual data analysis of 2751 patients Aliment Pharmacol Ther 17 99 109 10.1046/j.1365-2036.2003.01396.x (Pubitemid 36140439)
16. F Mégraud 2004 Basis for the management of drug-resistant Helicobacter pylori infection Drugs 64 1893 1904 10.2165/00003495-200464170- 00003 (Pubitemid 39243570)
17. F Megraud 2007 Helicobacter pylori and antibiotic resistance Gut 56 1502 10.1136/gut.2007.132514 (Pubitemid 350033185)
18. BJ Egan L Marzio H O'Connor C O'Morain 2008 Treatment of Helicobacter pylori infection Helicobacter 13 Suppl 1 35 40 10.1111/j.1523-5378.2008.00639.x
19. S Abid J Yakoob W Jafri Z Abbas K Mumtaz 2006 High prevalence of Clarithromycin resistance among patients with Helicobacter pylori infection: a study from a tertiary care center in Pakistan Helicobacter 11 Suppl 2 A39 10.1111/j.0083-8703.2006.00375.x
20. BC Wong FY Chang S Abid Z Abbas BR Lin C Van Rensburg PC Chen H Schneider AE Simjee SS Hamid A Seebaran J Zhang M Destefano SK Lam 2000 Triple therapy with clarithromycin, omeprazole, and amoxicillin for eradication of Helicobacter pylori in duodenal ulcer patients in Asia and Africa Aliment Pharmacol Ther 14 1529 1535 10.1046/j.1365-2036.2000.00863.x (Pubitemid 30944735)
21. LJ van Doorn PM Schneeberger N Nouhan AP Plaisier WG Quint WA de Boer 2000 Importance of Helicobacter pylori cagA and vacA status for the efficacy of antibiotic treatment Gut 46 321 326 10.1136/gut.46.3.321 (Pubitemid 30313381)
22. AW Sturm R van der Pol AJ Smits FM van Hellemondt SW Mouton B Jamil AM Minai GH Sampers 1997 Over-the-counter availability of antimicrobial agents, self-medication and patterns of resistance in Karachi, Pakistan J Antimicrob Chemother 39 543 547 10.1093/jac/39.4.543
23. ZT Zheng ZY Wang YX Chu YN Li QF Li SR Lin ZM Xu 1985 Double-blind short-term trial of furazolidone in peptic ulcer Lancet 1 8436 1048 1049
24. G Treiber S Ammon P Malfertheiner U Klotz 2002 Impact of furazolidone-based quadruple therapy for eradication of Helicobacter pylori after previous treatment failures Helicobacter 7 225 231 10.1046/j.1523-5378. 2002.00087.x (Pubitemid 34894175)
25. GM Buzás J Józan 2007 Nitrofuran-based regimens for the eradication of Helicobacter pylori infection J Gastroenterol Hepatol 22 1571 1581 10.1111/j.1440-1746.2007.05082.x (Pubitemid 47383342)
26. D Scott D Weeks K Melchers G Sachs 1998 The life and death of Helicobacter pylori Gut 43 Suppl 1 S56 S60
27. LA Fischbach S van Zanten J Dickason 2004 Meta-analysis: the efficacy, adverse events, and adherence related to first-line anti-Helicobacter pylori quadruple therapies Aliment Pharmacol Ther 20 1071 1082 10.1111/j.1365-2036. 2004.02248.x (Pubitemid 39657940)